The Florida-based Entopsis develops biomedical products for research and clinical use, with a focus on oncology, autoimmune disorders, metabolic disorders, and developing world malignancies. The company has established strategic collaborations with industry and academic researchers to advance its goals. Since its incorporation in 2011, Entopsis has utilized a proprietary material science screening platform to develop cost-effective and impactful products. The company's leading solutions include OpsisDx, a universal platform for diagnosing cancer and other diseases through urine, and PCRopsis, a series of time and cost-saving technologies for the life sciences.